Clinical Trial Update: A Novel, Regulated Gene Therapy (NGN-401) Study for Females With Rett Syndrome [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial to evaluate NGN-401, a gene therapy, for Rett syndrome in females is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rett Syndrome

Drugs mentioned

• NGN-401

Snippet

Sponsor: Neurogene Inc. | Conditions: Rett Syndrome | Phase 3 | Status: RECRUITING